The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Foon, Kenneth A.
    Boyiadzis, Michael
    Land, Stephanie R.
    Marks, Stanley
    Raptis, Anastasios
    Pietragallo, Louis
    Meisner, Dennis
    Laman, Andrew
    Sulecki, Mathew
    Butchko, Allyson
    Schaefer, Patricia
    Lenzer, Diana
    Tarhini, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 498 - 503
  • [22] Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia
    Wendtner, Clemens-Martin
    Gregor, Michael
    LEUKEMIA & LYMPHOMA, 2018, 59 (02) : 300 - 310
  • [23] Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?
    Cramer, Paula
    Langerbeins, Petra
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    Goede, Valentin
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 987 - 990
  • [24] Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    Kay, Neil E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 2889 - +
  • [25] Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
    Rossi, Davide
    Terzi-di-Bergamo, Lodovico
    De Paoli, Lorenzo
    Cerri, Michaela
    Ghilardi, Guido
    Chiarenza, Annalisa
    Bulian, Pietro
    Visco, Carlo
    Mauro, Francesca R.
    Morabito, Fortunato
    Cortelezzi, Agostino
    Zaja, Francesco
    Forconi, Francesco
    Laurenti, Luca
    Del Giudice, Ilaria
    Gentile, Massimo
    Vincelli, Iolanda
    Motta, Marina
    Coscia, Marta
    Rigolin, Gian Matteo
    Tedeschi, Alessandra
    Neri, Antonino
    Marasca, Roberto
    Perbellini, Omar
    Moreno, Carol
    Del Poeta, Giovanni
    Massaia, Massimo
    Zinzani, Pier Luigi
    Montillo, Marco
    Cuneo, Antonio
    Gattei, Valter
    Foa, Robin
    Gaidano, Gianluca
    BLOOD, 2015, 126 (16) : 1921 - 1924
  • [26] Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Zhou, Yi .
    Tang, Guilin
    Medeiros, L. Jeffrey
    McDonnell, Timothy J.
    Keating, Michael J.
    Wierda, William G.
    Wang, Sa A.
    MODERN PATHOLOGY, 2012, 25 (02) : 237 - 245
  • [27] Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration
    Delgado, Julio
    Ghita, Gabriela
    Baumann, Tycho
    Santacruz, Rodrigo
    Dlouhy, Ivan
    Aymerich, Marta
    Rozman, Maria
    Creus, Natalia
    Pereira, Arturo
    Montserrat, Emili
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (01) : 73 - 79
  • [28] Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
    Herishanu, Yair
    Tadmor, Tamar
    Braester, Andrei
    Bairey, Osnat
    Aviv, Ariel
    Rahimi-Levene, Naomi
    Fineman, Riva
    Levi, Itai
    Yuklea, Mona
    Ruchlemer, Rosa
    Shvidel, Lev
    Polliack, Aaron
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (02) : 185 - 192
  • [29] Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia
    Simkovic, Martin
    Vodarek, Pavel
    Motyckova, Monika
    ecsiova, Dominika
    Rozsivalova, Petra
    Mocikova, Heidi
    Stepankova, Pavla
    Sykorova, Alice
    Hrochova, Katerina
    Vrbacky, Filip
    Belada, David
    Zak, Pavel
    Smolej, Lukas
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [30] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Bosch, Francesc
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Tausch, Eugen
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Boettcher, Sebastian
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA, 2020, 34 (02) : 441 - 450
12345